Prot #Vedolizumab-3035: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic S

Project: Research project

Project Details

StatusFinished
Effective start/end date1/17/20 → 1/17/23

Funding

  • Pharmaceutical Research Associates, Inc. ((OE) Prot #Vedolizumab-3035 // (OE) Prot #Vedolizumab-3035)
  • Millennium Pharmaceuticals, Inc. ((OE) Prot #Vedolizumab-3035 // (OE) Prot #Vedolizumab-3035)